株式会社フェニックスバイオ

論文一覧

HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination

Zhang, B. H. Zhou, Y. Horrigan, S. Luckenbaugh, L. Hu, J. Zoulim, F. Zhang, Y. Y.
Mol Ther Methods Clin Dev. 2025 Nov 19;33(4):101646. doi: 10.1016/j.omtm.2025.101646.

READ MORE(PUB MED)

Netrin-1 inhibits the attachment and internalization of Hepatitis B virus for hepatocyte infection

Wang, Y. Murai, K. Ishida, A. Kawasaki, N. Kuroki, K. Li, Y. Y. Sato, Y. Miura, Y. Takara, K. Kong, L. Shimakami, T. Nio, K. Higuchi, Y.Suemizu, H. Ito, S. Yanagawa, H. Kaneko, S. Yamashita, T. Honda, M.
PLoS Pathog. 2025 Dec 17;21(12):e1013776. doi: 10.1371/journal.ppat.1013776.

READ MORE(PUB MED)

Cholesterol uptake capacity of HDL in culture medium of fresh primary human hepatocytes: an in vitro system for screening anti-atherosclerosis drugs focused on HDL functions

Hata, K. Okada, T. Takahashi, M. Arimatsu, Y. Kawahira, J. Murakami, K. Harada, A. Yoshikawa, N. Inamatsu, M. Kakuni, M.
BMC Res Notes. 2025 Nov 13;18(1):480. doi: 10.1186/s13104-025-07515-6.

READ MORE(PUB MED)

Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity

Nakayama, M. Takagi-Maeda, S. Machino, Y. Nihira, K. Inoue, M. Takahashi, N. Usami, K.
Oncol Rep. 2025 Nov;54(5):155. doi: 10.3892/or.2025.8988.

READ MORE(PUB MED)

An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

Kawamoto, K. Shimotsuma, Y. Maeda, K. Matsunaga, K. Asano, H. Cohen, S. M. Yamada, T.

Arch Toxicol. 2025 Sep;99(9):3803-3824. doi: 10.1007/s00204-025-04099-9.

READ MORE(PUB MED)

Replication-driven HBV cccDNA loss in chimeric mice with humanized livers

Zhang, B. H. Zhou, Y. Horrigan, S. Zoulim, F. Hu, J. Zhang, Y. Y.
J Virol. 2025 Nov 6:e0129525. doi: 10.1128/jvi.01295-25.

READ MORE(PUB MED)

Quantitative prediction of CYP2C9-mediated drug disposition using humanized mice

Fujita, Yuito Tsutsui, Haruka Hirabayashi, Manabu Shimojo, Tomofumi Tachibana, Tatsuhiko Emoto, Chie Shindoh, Hidetoshi Terao, Kimio Miyake, Taiji
Drug Metab Dispos. 2025 Oct 17;53(12):100185. doi: 10.1016/j.dmd.2025.100185.

READ MORE(PUB MED)

Mode of action analysis for mouse liver tumor formation by MGK-264 and human relevance

Yano, J. Kawamoto, K. Shimotsuma, Y. Ogata, K. Matsunaga, K. Abe, J. Fukunaga, S. Osimitz, T. G. Lake, B. G. Asano, H.
Regul Toxicol Pharmacol. 2025 Dec;163:105929. doi: 10.1016/j.yrtph.2025.105929.

READ MORE(PUB MED)

RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking

Gad, S. A. Abo Elwafa, D. A. Hussein, S. A. Fukano, K. Kato, T. Shoji, I. Chayama, K. Muramatsu, M. Isogawa, M. Wakita, T. Merk, D. Aly, H. H.
Antiviral Res. 2025 Aug;240:106214. doi: 10.1016/j.antiviral.2025.106214.

READ MORE(PUB MED)

A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide

Rsi Suwardana, G. N. Abe, T. Deng, L. Matsui, C. Okitsu, T. Yamada, T. Hatano, M. Wiriyasermkul, P. Nagamori, S. Gad, S. A. Aly, H. H. Nishitsuji, H. Shimotohno, K. Shoji, I.
Antiviral Res. 2025 Aug 30;243:106267. doi: 10.1016/j.antiviral.2025.106267.

READ MORE(PUB MED)

Potential for Core Fucose-Targeted Therapy Against HBV Infection of Human Normal Hepatocytes

Takamatsu, S. Morita, C. Sakon, D. Nakamura, K. Hishii, H. Kondo, J. Ueda, K. Miyoshi, E.
Viruses. 2025 Sep 15;17(9):1242. doi: 10.3390/v17091242.

READ MORE(PUB MED)

Species-specific gene expression manipulation in humanized livers of chimeric mice via siRNA-encapsulated lipid nanoparticle treatment

Yamazaki, K. Kubara, K. Sugahara, G. Muto, H. Yamamoto, M. Mano, Y. Mitsuhashi, K. Yamasaki, C. Ishida, Y. Tateno, C. Suzuki, Y.
Mol Ther Methods Clin Dev. 2025 Apr 14;33(2):101466. doi: 10.1016/j.omtm.2025.101466.

READ MORE(PUB MED)

Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK__ model with enterohepatic circulation

Hirasawa, K. Adachi, T. Takeuchi, H. Kuroda, T. Abe, J. Nakajima, M.
Toxicol Appl Pharmacol. 2025 Aug 19;504:117525. doi: 10.1016/j.taap.2025.117525.

READ MORE(PUB MED)

Modeling of hepatitis B virus infection spread in primary human hepatocytes

Shi, Z. Tsuge, M. Collier, N. Takeuchi, Y. Uchida, T. Rutter, C. M. Teraoka, Y. Uprichard, S. L. Ishida, Y. Tateno, C. Ozik, J. Dahari, H. Chayama, K.
J Virol. 2025 Aug 4:e0092725. doi: 10.1128/jvi.00927-25.

READ MORE(PUB MED)

Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model

Visser, B. J. Biswas, S. Eltahan, R. Fares-Gusmao, R. Yegneswaran, S. Mufti, N. Villa, C. H. McGivern, D. R.
Transfusion. 2025 Jul 24. doi: 10.1111/trf.18357.

READ MORE(PUB MED)

miRNA-29b-1-5p mediates an antiviral activity by targeting the HBV entry receptor in human hepatocytes

Gailhouste, L. Furutani, Y. Qin, X. Y. Higuchi, S. Toguchi, M. Yanaka, K. Watashi, K. Wakita, T. Kojima, S.
Sci Rep. 2025 Jul 3;15(1):23725. doi: 10.1038/s41598-025-09655-y.

READ MORE(PUB MED)

Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection

Zhou, J. Kaiser, H. Rocha, E. Terrell, A. N. Corti, D. Purcell, L. A. Lempp, F. A. Puschnik, A. S.
JHEP Rep. 2025 Mar 22;7(6):101400. doi: 10.1016/j.jhepr.2025.101400. eCollection

READ MORE(PUB MED)

An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

Kawamoto, K.Shimotsuma, Y.Maeda, K. Matsunaga, K. Asano, H. Cohen, S. M. Yamada, T.
Arch Toxicol. 2025 Jun 9. doi: 10.1007/s00204-025-04099-9.

READ MORE(PUB MED)

Quantitative Prediction of Drug-Drug Interactions Arising from CYP3A4 Induction using Chimeric Mice with Humanized Liver

Nakayama, K. Negoro, T. Takubo, H. Hayashi, A. Taniguchi, T. Nomura, Y. Iwanaga, K.
Xenobiotica. 2025 Jun 11:1-19. doi: 10.1080/00498254.2025.2518239.

READ MORE(PUB MED)

Clinical potential of SAG-524: A novel HBV RNA destabilizer with a unique mechanism of action

Tanaka, Yasuhito
Glob Health Med. 2025 Feb 28;7(1):64-66. doi: 10.35772/ghm.2024.01078.

READ MORE(PUB MED)